https://www.thebostonexaminer.com/article/907002440-mayhew-tools-launches-new-3-pc-long-non-turning-pneumatic-set The Boston Examiner en PressRelease 2026-04-20T21:03:19+00:00 Mayhew Tools Launches New 3 Pc. Long Non-Turning Pneumatic Set https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/22821933-mayhew-tools-2000x1260.png https://www.thebostonexaminer.com/article/906282724-heygears-unveils-one-stop-3d-printing-solutions-for-elastomer-transparent-engineering-applications-at-rapid-tct-2026 The Boston Examiner en PressRelease 2026-04-20T16:00:00+00:00 HeyGears Unveils One-Stop 3D Printing Solutions for Elastomer, Transparent & Engineering Applications at RAPID+TCT 2026 https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24835056-heygears-elastomer-3d-printing-1280x959.png https://www.thebostonexaminer.com/article/907008228-aktualisierung-bvi-gibt-bekannt-dass-virtuoso-eine-neue-chirurgische-plattform-mit-doppelfunktion-die-ce-kennzeichnung-gem-eu-mdr-erhalten The Boston Examiner en PressRelease 2026-04-20T21:28:54+00:00 AKTUALISIERUNG -- BVI gibt bekannt, dass Virtuoso®, eine neue chirurgische Plattform mit Doppelfunktion, die CE-Kennzeichnung gemäß EU-MDR erhalten hat https://ml.globenewswire.com/media/NjNkNTUyMTQtMGZiYS00MTczLTkxNDYtN2IxMmI2YTU0ZmMyLTEyNjQwMzItMjAyNi0wNC0yMC1kZQ==/tiny/BVI-Medical-Inc-.png https://www.thebostonexaminer.com/article/907008243-mise-jour-bvi-annonce-l-obtention-du-marquage-ce-au-titre-du-r-glement-europ-en-sur-les-dispositifs-m-dicaux-pour-virtuoso-une-toute-nouvelle The Boston Examiner en PressRelease 2026-04-20T21:28:54+00:00 MISE À JOUR -- BVI annonce l’obtention du marquage CE au titre du Règlement européen sur les dispositifs médicaux pour Virtuoso®, une toute nouvelle plateforme chirurgicale à double fonction https://ml.globenewswire.com/media/NjNkNTUyMTQtMGZiYS00MTczLTkxNDYtN2IxMmI2YTU0ZmMyLTEyNjQwMzItMjAyNi0wNC0yMC1mcg==/tiny/BVI-Medical-Inc-.png https://www.thebostonexaminer.com/article/907000429-cargurus-to-report-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-04-20T20:05:00+00:00 CarGurus To Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/5e9ed825-143d-405a-9794-acd1a1ded2cc/small/cg-logo-2025-small-png.png https://www.thebostonexaminer.com/article/907000699-amwell-to-report-first-quarter-2026-operating-results The Boston Examiner en PressRelease 2026-04-20T20:05:00+00:00 Amwell® to report first quarter 2026 operating results https://ml.globenewswire.com/media/ff1989f5-0a6a-4e00-99dc-cb29a818aca5/small/amwell-logo-blue-2023-v02-rgb-2-png.png https://www.thebostonexaminer.com/article/907001167-kailera-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares The Boston Examiner en PressRelease 2026-04-20T20:05:00+00:00 Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/c0b33a3d-0c2b-45b0-ace8-6ff585b41339/small/kailera-logo-png.png https://www.thebostonexaminer.com/article/907000519-flywire-to-announce-first-quarter-2026-earnings-on-may-5-2026 The Boston Examiner en PressRelease 2026-04-20T20:00:00+00:00 Flywire to Announce First Quarter 2026 Earnings on May 5, 2026 https://ml.globenewswire.com/media/9b1123f3-5f90-4036-ab7b-c4c3d1f5491b/small/flywire-logo-jpg.jpg https://www.thebostonexaminer.com/article/906982674-lung-cancer-therapeutics-market-to-reach-49-5-billion-by-2030-driven-by-rising-cancer-incidence-and-r-d-investment-surge The Boston Examiner en PressRelease 2026-04-20T18:19:26+00:00 Lung Cancer Therapeutics Market to Reach $49.5 Billion by 2030, Driven by Rising Cancer Incidence and R&D Investment Surge https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.thebostonexaminer.com/article/906954630-bvi-announces-ce-mark-under-eu-mdr-for-virtuoso-a-brand-new-dual-function-surgical-platform The Boston Examiner en PressRelease 2026-04-20T14:00:00+00:00 BVI Announces CE Mark Under EU MDR for Virtuoso®, A Brand New Dual-Function Surgical Platform https://ml.globenewswire.com/media/0e7f0025-cd6d-4b42-9d31-9d16f1b74c40/small/bvi-logo-png.png https://www.thebostonexaminer.com/article/906950148-hinweis-zum-nichtbeachten-bvi-medical-inc The Boston Examiner en PressRelease 2026-04-20T13:46:44+00:00 HINWEIS ZUM NICHTBEACHTEN -- BVI Medical, Inc. https://ml.globenewswire.com/media/0e7f0025-cd6d-4b42-9d31-9d16f1b74c40/small/bvi-logo-png.png https://www.thebostonexaminer.com/article/906950152-avis-ignorer-bvi-medical-inc The Boston Examiner en PressRelease 2026-04-20T13:46:44+00:00 AVIS À IGNORER -- BVI Medical, Inc. https://ml.globenewswire.com/media/0e7f0025-cd6d-4b42-9d31-9d16f1b74c40/small/bvi-logo-png.png https://www.thebostonexaminer.com/article/906945990-payscale-intelligence-cloud-sets-new-standard-in-compensation-intelligence The Boston Examiner en PressRelease 2026-04-20T13:00:00+00:00 Payscale Intelligence Cloud Sets New Standard in Compensation Intelligence https://ml.globenewswire.com/media/8d98e996-808c-4de5-8b7e-15bec433c6f4/small/payscale-full-logo-dark-png.png https://www.thebostonexaminer.com/article/906946091-immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in The Boston Examiner en PressRelease 2026-04-20T13:00:00+00:00 Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://www.thebostonexaminer.com/article/906946361-velocity-logic-group-and-paytronix-partner-to-extend-loyalty-engagement-to-every-pump-transaction The Boston Examiner en PressRelease 2026-04-20T13:00:00+00:00 Velocity Logic Group and Paytronix Partner to Extend Loyalty Engagement to Every Pump Transaction https://ml.globenewswire.com/media/a0a47d40-4419-436d-b187-246e25669b64/small/access-paytronix-dark-002-1-png.png https://www.thebostonexaminer.com/article/906941093-akari-therapeutics-reports-positive-preclinical-data-for-aktx-101-demonstrating-differentiated-cytotoxicity-for-first-in-class-trop2-adc-payload The Boston Examiner en PressRelease 2026-04-20T12:35:00+00:00 Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://www.thebostonexaminer.com/article/906936761-fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-april-27-2026-at-8-00-a-m-et The Boston Examiner en PressRelease 2026-04-20T12:00:00+00:00 Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png https://www.thebostonexaminer.com/article/906937116-bvi-gibt-bekannt-dass-virtuoso-eine-neue-chirurgische-plattform-mit-doppelfunktion-die-ce-kennzeichnung-gem-eu-mdr-erhalten-hat The Boston Examiner en PressRelease 2026-04-20T12:00:00+00:00 BVI gibt bekannt, dass Virtuoso®, eine neue chirurgische Plattform mit Doppelfunktion, die CE-Kennzeichnung gemäß EU-MDR erhalten hat https://ml.globenewswire.com/media/0e7f0025-cd6d-4b42-9d31-9d16f1b74c40/small/bvi-logo-png.png https://www.thebostonexaminer.com/article/906937119-bvi-annonce-l-obtention-du-marquage-ce-au-titre-du-r-glement-europ-en-sur-les-dispositifs-m-dicaux-pour-virtuoso-une-toute-nouvelle-plateforme The Boston Examiner en PressRelease 2026-04-20T12:00:00+00:00 BVI annonce l’obtention du marquage CE au titre du Règlement européen sur les dispositifs médicaux pour Virtuoso®, une toute nouvelle plateforme chirurgicale à double fonction https://ml.globenewswire.com/media/0e7f0025-cd6d-4b42-9d31-9d16f1b74c40/small/bvi-logo-png.png https://www.thebostonexaminer.com/article/906932351-biogen-enters-into-agreement-with-tj-biopharma-for-felzartamab-assets-in-the-greater-china-region The Boston Examiner en PressRelease 2026-04-20T11:30:00+00:00 Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg https://www.thebostonexaminer.com/article/906931981-seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026 The Boston Examiner en PressRelease 2026-04-20T11:00:00+00:00 Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.thebostonexaminer.com/article/906932245-monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-cancer-research-aacr-annual-meeting-2026-on-the-potential-of-its The Boston Examiner en PressRelease 2026-04-20T11:00:00+00:00 Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors https://ml.globenewswire.com/media/20ed9999-454a-4e2a-aabc-217270a87d2d/small/mrtx-logo-primaryblue-4cp-jpg.jpg https://www.thebostonexaminer.com/article/906932319-seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026 The Boston Examiner en PressRelease 2026-04-20T11:00:00+00:00 Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.thebostonexaminer.com/article/906891444-schneider-electric-and-deloitte-collaborate-to-drive-ai-enabled-digital-transformation-across-industrial-operations The Boston Examiner en PressRelease 2026-04-20T06:00:00+00:00 Schneider Electric and Deloitte collaborate to drive AI-enabled digital transformation across industrial operations https://ml.globenewswire.com/media/5d185555-b771-4931-ba37-33a6fc1f5d24/medium/schneider-electric-and-deloitte-collaborate-to-drive-ai-enab.jpg https://www.thebostonexaminer.com/article/906529761-my-american-goods-secures-trademark-as-it-expands-hybrid-marketplace-model The Boston Examiner en PressRelease 2026-04-19T10:08:02+00:00 My American Goods® Secures Trademark as It Expands Hybrid Marketplace Model https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24835639-my-american-goods-homepage-1280x720.png https://www.thebostonexaminer.com/article/906786185-molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin The Boston Examiner en PressRelease 2026-04-19T16:00:00+00:00 Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg https://www.thebostonexaminer.com/article/906711088-challenge-accepted-schneider-electric-helps-industry-turn-toughest-problems-into-competitive-advantage The Boston Examiner en PressRelease 2026-04-19T07:00:00+00:00 Challenge accepted: Schneider Electric helps industry turn toughest problems into competitive advantage https://ml.globenewswire.com/media/f9f1757e-4ed3-4fe7-939b-35cd2b1f43e1/medium/schneider-electric.jpg